<DOC>
	<DOCNO>NCT01801137</DOCNO>
	<brief_summary>A study determine efficacy Everolimus ( AfinitorÂ® ) third line therapy patient transitional cell carcinoma urothelium fail progress two line chemotherapy</brief_summary>
	<brief_title>The Efficacy RAD 001 Second Line Therapy Patients With Transitional Cell Carcinoma TCC Urothelium</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Provision write informed consent Male female age 18 year Histologically prove transitional cell carcinoma urothelium Metastatic locally advance disease amenable curative surgery and/or radiotherapy Recurrence progression least one chemotherapy regimen unresectable/advanced disease No 2 line previous chemotherapy.. Measurable disease ( RECIST criterion ) Previously irradiate lesion consider measurable ECOG performance status 0 , 1 2 No prior treatment anti cancer agent , include radiotherapy , last 4 week . No currently active CNS involvement No pregnancy . Women child bear potential must negative pregnancy test . No uncontrolled diabetes No symptomatic coronary artery disease , myocardial infarction within last six month , congestive cardiac failure great New York Heart Association ( NYHA ) class II , uncontrolled symptomatic cardiac arrhythmia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>